INCY Incyte Corporation
INCY Incyte Corporation
Healthcare · Biotechnology
Market read
Scan convergence 2 scans as of 2026-08-17 2 bull converging
POC $100.42 · VWAP $99.60 · +24.0% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
INCY Price Structure
Loading timeframes…
Peers
Every watchlist INCY belongs to, members best 30-day change first — INCY highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
Against street estimates
How INCY's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about INCY from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising Pipeline Developments
- Incyte (INCY) Earnings Report Q2 2026 | Miss, EPS & Revenue
- Incyte Corporation (INCY) First Quarter 2026 Earnings Recap: Revenue Jumps 21% on Portfolio Strength
- Incyte Corp. (INCY) Q1 2026 Earnings: Strong EPS Beat
- INCY Q1 2026 Earnings: $1.27B Revenue, $303.33M Net Income
INCY research tape
36 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.